Literature DB >> 2038342

v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells.

H J Voeller1, G Wilding, E P Gelmann.   

Abstract

The LNCaP human prostate cancer cell line is dependent on androgen for in vitro growth. To discover genes that may be responsible for progression of prostate cancer from hormone dependence to hormone independence, we transfected LNCaP cells with expression vectors that contained either the v-rasH or c-rasH gene under the control of the cadmium (Cd2+)-inducible human metallothionein-IIA promoter. Numerous derivative cell lines were isolated which manifested inducible expression of rasH p21 protein when the cells were treated with Cd2+. None of the cell lines transfected with c-rasH were found to have an altered growth phenotype. Several derivative cell lines expressing inducible v-rasH manifested hormone-independent growth in culture when treated with 10(-7) M Cd2+ . Cd2+ induction of v-rasH p21 was also shown to increase anchorage-independent colony formation of the v-rasH-expressing cell lines tested. Expression of a dominant mutated oncogene can change the hormone-dependent growth phenotype of prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2038342     DOI: 10.1210/mend-5-2-209

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  13 in total

1.  Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice.

Authors:  Vanessa Fritz; Zohra Benfodda; Geneviève Rodier; Corinne Henriquet; François Iborra; Christophe Avancès; Yves Allory; Alexandre de la Taille; Stéphane Culine; Hubert Blancou; Jean Paul Cristol; Françoise Michel; Claude Sardet; Lluis Fajas
Journal:  Mol Cancer Ther       Date:  2010-06-08       Impact factor: 6.261

2.  Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer.

Authors:  Hui Gao; Xuesong Ouyang; Whitney A Banach-Petrosky; William L Gerald; Michael M Shen; Cory Abate-Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-14       Impact factor: 11.205

3.  Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase.

Authors:  L F Lee; J Guan; Y Qiu; H J Kung
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

Review 4.  Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic Era.

Authors:  Juan M Arriaga; Cory Abate-Shen
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

5.  Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects).

Authors:  Kenneth V Honn; Amer Aref; Yong Q Chen; Michael L Cher; John D Crissman; Jeffrey D Forman; Xiang Gao; David Grignon; Maha Hussain; Arthur T Porter; Edson J Pontes; Bruce Redman; Wael Sakr; Richard Severson; Dean G Tang; David P Wood
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

6.  Effects of sex steroids on cell growth and C-myc oncogene expression in LN-CaP and DU-145 prostatic carcinoma cell lines.

Authors:  F K Asadi; R Sharifi
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

7.  Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer.

Authors:  Glenn Liu; Kurt Oettel; Howard Bailey; Lynn Van Ummersen; Kendra Tutsch; Mary Jane Staab; Dorothea Horvath; Dona Alberti; Rhoda Arzoomanian; Hamied Rezazadeh; James McGovern; Emily Robinson; David DeMets; George Wilding
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

8.  ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.

Authors:  Alvaro Aytes; Antonina Mitrofanova; Carolyn Waugh Kinkade; Celine Lefebvre; Ming Lei; Vanessa Phelan; H Carl LeKaye; Jason A Koutcher; Robert D Cardiff; Andrea Califano; Michael M Shen; Cory Abate-Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-05       Impact factor: 11.205

Review 9.  The endocrine disruptor cadmium: a new player in the pathophysiology of metabolic diseases.

Authors:  V M Bimonte; Z M Besharat; A Antonioni; V Cella; A Lenzi; E Ferretti; S Migliaccio
Journal:  J Endocrinol Invest       Date:  2021-01-26       Impact factor: 4.256

10.  Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways.

Authors:  Barbara Wegiel; Thomas Jiborn; Magnus Abrahamson; Leszek Helczynski; Leo Otterbein; Jenny Liao Persson; Anders Bjartell
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.